We report a 67-year-old woman with mycosis fungoides (MF) who was receiving subcutaneous injections of recombinant interferon α-2b (IFN-α). After 2 months of IFN-α treatment, bullous lesions appeared on her trunk and extremities. A skin biopsy specimen from the trunk revealed histopathologic features of bullous MF. Bullous lesions with specific infiltrates of MF are very rare; to the best of our knowledge, this is the first case showing specific bullous lesions of MF developed under IFN-α treatment.

Keywords:
Cutaneous T cell lymphoma, Bullous mycosis fungoides, Interferon α
1.
Kaposi M: Mycosis fungoides und ihre Beziehungen zu anderen ähnlichen Krankheiten. Wien Med Wochenschr 1887;20:642–646.
2.
Garb S, Wise F: Mycosis fungoides with bullous lesions. Arch Dermatol Syphilol 1943;48: 359–368.
3.
Konrad K: Mycosis fungoides bullosa; in Christophers E, Goos M (eds): Lymphoproliferative Diseases of the Skin. New York, Springer, 1989, pp 157–162.
4.
Maeda K, Jimbow K, Takahashi M: Association of vesiculobullous eruptions with mycosis fungoides. Dermatologica 1987;174:34–38.
5.
Roenigk HH, Castrovinci AJ. Mycosis fungoides bullosa. Arch Dermatol 1971;104:402– 406.
6.
Kartsonis J, Brettschneider F, Weissmann A, Rosen L: Mycosis fungoides bullosa. Am J Dermatopathol 1990;12:76–80.
7.
Preesman AH, Toonstra J, van der Putte SCJ, de Geer DB, van Weelden H, van Vloten WA: UV-B-induced bullous pemphigoid restricted to mycosis fungoides plaques. Clin Exp Dermatol 1990;15:363–366.
8.
Zina G, Bernengo MG, Zina AM: Bullous Sézary syndrome. Dermatologica 1981;163: 25–33.
9.
Asnis LA, Gaspari AA: Cutaneous reactions to recombinant cytokine therapy. J Am Acad Dermatol 1995;33:393–410.
10.
Andry P, Weber-Buisset MJ, Fraitag S, Brechot C, De Prost Y: Toxidermie bulleuse à intron A. Ann Dermatol Vénéréol 1993;120:843–845.
11.
Platanias LC: Interferons: Laboratory to clinic investigations. Curr Opin Oncol 1995;7:560– 565.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.